Brian Loggie, M.D.

One of the few experts in peritoneal mesothelioma, Dr. Brian Loggie studies and treats one of the rarest cancer types, the second most common type of mesothelioma. Dr. Loggie is currently the Harold J. Bonstetter Professor of Surgery at the Creighton University School of Medicine  in Omaha, Nebraska. He is also chief of surgical oncology and director at Creighton University Medical Center’s Cancer Biology Program.

Dr. Loggie is a widely-respected expert in the field of cancers of the abdominal cavity, including peritoneal mesothelioma. He is also an expert in metastatic cancers, helping develop novel treatments like heated intraperitoneal chemotherapy, a once uncommon treatment now widely used. Dr. Loggie also belongs to several professional organizations and holds patents from his research.

Areas of Expertise

Dr. Loggie’s areas of expertise mostly include surgical oncology, the surgical treatment of cancers. He also specializes in treating rare cancers and orphan diseases. These include peritoneal mesothelioma, peritoneal carcinomatosis, cutaneous malignant melanoma, pseudomyxoma peritonei, and abdominopelvic and retroperitoneal sarcomas. He also has expertise in managing patient care and treatment for complicated and recurrent tumors.

Education and Early Career

Dr. Loggie’s education began with an undergraduate degree from Loyola College in Montreal, Quebec. He then earned his medical degree at McGill University in Montreal. Dr. Loggie completed a surgical residency program at Montreal General Hospital and earned a graduate degree from McGill in experimental surgery. He then went on to complete clinical and research fellowships at the University of Illinois at Chicago.

In his early career, Dr. Loggie held faculty positions in Chicago at the University of Illinois, the Bowman Gray School of Medicine in Winston-Salem, North Carolina, and the University of Texas Southwestern Medical Center in Dallas, Texas. During his time in Winston-Salem at Wake Forest University Baptist Medical Center , he helped develop a novel new treatment for peritoneal mesothelioma, called HIPEC.

Development of HIPEC

Dr. Loggie is a pioneer of HIPEC, or heated intraperitoneal chemotherapy. He began working on this procedure in the early 1990s, when it was virtually unheard of. HIPEC uses surgery to remove the bulk of tumors in the abdominal cavity, then circulates heated chemotherapy drugs to target remaining cancer cells. It works remarkably well, giving hope to patients who thought they lacked options. Today the treatment is almost standard.

Current Position and Research

Dr. Loggie is currently the chief of oncology surgery and a professor at Creighton University. At Creighton, he teaches medical students, guides fellowships and residencies, and directs the Cancer Biology Program. Dr. Loggie conducts research into rare cancers and diseases, including peritoneal mesothelioma. In addition to his HIPEC research, Dr. Loggie also studies genetic factors in mesothelioma and other rare cancers.

Honors and Organizations

With his expertise and dedication to patient care, treatment research, Dr. Loggie is a member of several prestigious professional organizations. His memberships include the Royal College of Surgeons of Canada, the Society of Surgical Oncology, the Southeastern Surgical Congress, the American College of Surgeons, the Association for Academic Surgery, and the Canadian Association of General Surgeons.

Every year since 2001, Dr. Loggie has been included in the Best Doctors in America. In 2010, he won the Creighton University Magis Award for his work with a team of surgeons that traveled to Haiti. Together the team administered emergency treatment and surgery to earthquake victims.

Any patient with a rare cancer, orphan disease, or peritoneal mesothelioma could benefit from Dr. Loggie’s care and expertise. His extensive experience and research with these diseases has made him an expert in many areas of medicine most doctors know little about. Many patients with rare diseases or with few treatment options rely on Dr. Loggie for hope and excellent care.